Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928337 · ClinicalTrials.gov registry record
Data Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.
A clinical trial of Fertility Disorders, sponsored by Fairtility.
- Recruiting
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT06928337: Recruiting study of Fertility Disorders, sponsored by Fairtility.
NCT06928337 is a study of Fertility Disorders that is actively recruiting participants, run by Fairtility. The registered enrollment target is 350 participants, below the 1,478-participant average among 3 other Fertility Disorders trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06928337, a study of Fertility Disorders, is actively recruiting participants, sponsored by Fairtility.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
This data collection protocol is aimed to allow the reliable and robust development (training, verification, and validations) of CHLOE technology-based applications as well as improve the machine learning stage of released devices/applications. Additionally, a simulated use assessments will be conducted to ensure the correct and easy use of the CHLOE applications.
Conditions Studied
Interventions
- DEVICE AI evaluation of oocytes.
Study Locations (1)
Arizona
- The World Egg and Sperm Bank - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-05-01 |
What NCT06928337 shows while recruiting
NCT06928337 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 1,478-participant average among 3 other Fertility Disorders trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Fertility Disorders appearing as the primary indexed condition, and to 1 intervention - of which AI evaluation of oocytes. is the first listed.
NCT06928337 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06928337 about?
NCT06928337 is a clinical study titled "Data Collection Protocol for the Development of CHLOE-OQ, an AI Model for Assessing Oocytes Quality.". This data collection protocol is aimed to allow the reliable and robust development (training, verification, and validations) of CHLOE technology-based applications as well as improve the machine learning stage of released devices/applications. Additionally, a simulated use assessments will be condu...
What is the current status of trial NCT06928337?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2025-05-01. Estimated completion is 2026-05-01.
What conditions does trial NCT06928337 study?
This clinical trial studies the following conditions: Fertility Disorders.
What interventions are being tested in trial NCT06928337?
The interventions under investigation include: AI evaluation of oocytes. (DEVICE).
Who is sponsoring clinical trial NCT06928337?
This trial is sponsored by Fairtility, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928337 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fertility Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI